恩替卡韦治疗乙型肝炎失代偿期肝硬化的近期疗效观察

Clinical observation about entecavir in treating decompensated cirrhosis due to hepatitis B at initial stage

目的:观察恩替卡韦治疗乙型肝炎肝硬化失代偿期患者24周时的疗效。方法:乙型肝炎肝硬化失代偿期患者36例,采用恩替卡韦0.5mg/d,与32例对照组单纯支持对症治疗比较,观察24周时两组患者肝功能、Child-Pugh分级以及血清HBV DNA自基线下降的水平。结果:治疗24周时治疗组患者肝功能、Child-Pugh分级以及血清HBV DNA自基线下降的水平与对照组比较差异有显著性意义。结论:恩替卡韦能改善乙型肝炎肝硬化失代偿期患者肝功能,并能取得良好的抗病毒效果,提高生存率。

Objective： To evaluate the efficacy of entecavir in treating decompensated cirrhosis due to chronic hepatitis B, Methods： Sixty-eight patients with decompensated cirrhosis of hepatitis B virus infection were randomly divided treatment group （36 cases） and control group （32 cases） , which were matched for liver function, Child-Pugh score, and reductions of serum HBV DNA from baseline （copies/ml） at week 24. Treatment group were treated with entecavir 0. 5 mg orally once daily, and supportive treatment. Results： There were significant difference in liver function, Child-Pugh score, and reductions of serum HBV DNA from baseline （copies/ml） at week 24 between the two groups. Conclusion： Entecavir therapy can result in a significant improvement of liver function and the prolonging of survival time in patients with decompensated HBV cirrhosis, and can decrease serum HBV DNA effectively.